Precision Bio rises as U.S. patents bolster experimental hepatitis B therapy

Precision Biosciences

11/03/2026 11:14

** Shares of  biotech firm Precision BioSciences DTIL.O rise 1% to $5.32 premarket

** Co says the U.S. Patent and Trademark Office issued notices strengthening IP for PBGENE‑HBV, its experimental gene‑editing therapy for chronic hepatitis B, a long‑lasting liver infection

** Says the patents will cover its proprietary gene‑editing enzyme and a new component that may be used in future therapies, with protection expected to last until at least November 2044

** PBGENE‑HBV is in a first‑in‑human global trial and aims to eliminate the form of the virus that allows it to persist in the body - DTIL

** Co says the program has U.S. FDA fast-track status

** Shares rose ~9% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))